The US Food and Drug Administration (FDA) approved the emergency use of a novel coronavirus infection (Corona 19) vaccine developed by Janssen, a subsidiary of the US pharmaceutical company Johnson & Johnson (J&J) on the 27th of last month. FDA accepted the recommendation the day before by the Vaccine and Biological Medicines Advisory Committee (VRBPAC), an external advisory body.
Overall effect 66%, severe blockage 85%
Korea, 6 million people are coming in from April
As a result, there are three Corona 19 vaccines available in the United States, following Pfizer and Modena. The J&J vaccine is a one-time vaccine for COVID-19, which has been approved for the first time in the United States, and can be extended to remote workers who are difficult to inject twice at regular intervals. Accessibility is high because it is stored refrigerated.
In a clinical trial involving 40,000 people in the United States, South America, and South Africa, the overall preventive effect was 66%, and the effect of preventing the development of a severe or serious condition was 85%. There was no case of death from Corona 19 after vaccination. The preventive effects of Pfizer and Modena vaccines were reported in 94% and 95%, respectively, in clinical trials in the United States.
In Korea, the Ministry of Food and Drug Safety initiated the review as Janssen applied for an item permission on the 27th of last month. The Ministry of Food and Drug Safety is planning to decide whether to approve or not within up to 40 days after checking the safety and efficacy through triple consultation of the Verification Advisory Group, the Central Pharmacy Review Committee, and the Final Inspection Committee. If it is approved in March and passed the national shipment approval process, the April vaccination is also possible. The government is planning to pre-purchase 6 million doses of J&J vaccine and bring them in one after another from April.
Washington = correspondent Park Hyun-young, reporter Hwang Soo-yeon [email protected]
